Shattuck Labs to Present Virtually at Cowen 4th Annual IO Next Summit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Austin, TX and Durham, NC – November 6, 2020 – Shattuck Labs (NASDAQ: STTK), a clinical-stage biotechnology company focused on bi-functional fusion proteins for cancer and autoimmune disease treatment, announced participation in the Cowen 4th Annual IO Next Summit on November 13, 2020. CEO Taylor Schreiber and senior executives will join a fireside chat with analyst Marc Frahm. The presentation is scheduled for 2:15 p.m. EST and can be accessed via a webcast. Shattuck's innovative ARC® platform develops therapies inhibiting immune checkpoints while activating costimulatory pathways.
Details
News Market Reaction – STTK
The recorded move for STTK in the trading session of this news was -4.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX and DURHAM, NC, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Chief Executive Officer, and other senior executives will participate in the Cowen 4th Annual IO Next Summit 2020 on November 13, 2020.
Conference Presentation Details
Conference: Cowen 4th Annual IO Next Summit
Format: Fireside chat with covering analyst, Marc Frahm, Ph.D.
Date: November 13, 2020
Time: 2:15 p.m. EST
Webcast Link: Available Here
The live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.